

ERRATUM

In the article "A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor" by Bisgaier et al. which appeared in the January 1998 issue of the *Journal of Lipid Research* (39: 17-30), there was a typographical error in Table 1. In the first column, headed "Plasma Determinant," "ApoC-I" should be "ApoC-II." The corrected table is reproduced below.

TABLE 1. Plasma apolipoprotein and lipid levels in gemfibrozil-, PD 69405-, and PD 72953-treated male Sprague-Dawley rats

Plasma Determinant	Control (n = 5)	Gemfibrozil 100 mg/kg (n = 5)	PD 69405 30 mg/kg (n = 5)	PD 69405 100 mg/kg (n = 5)	PD 72953 30 mg/kg (n = 5)	PD 72953 100 mg/kg (n = 5)
			<i>mg/dL</i>			
Triglycerides	83 ± 10	43 ± 7 ^d	61 ± 6 ^e	39 ± 4 ^e	34 ± 5 ^e	15 ± 2 ^e
VLDL cholesterol	5.1 ± 0.8	2.7 ± 0.6 ^c	3.7 ± 0.6	1.9 ± 0.2 ^e	1.4 ± 0.2 ^e	0.5 ± 0.1 ^e
LDL cholesterol	10.6 ± 1.4	3.7 ± 0.6 ^e	5.3 ± 0.4 ^e	1.2 ± 0.2 ^e	3.5 ± 0.7 ^e	3.3 ± 1.0 ^e
HDL cholesterol	33 ± 2	39 ± 1	34 ± 2	34 ± 4	51 ± 6 ^a	61 ± 9 ^d
			<i>percent of control</i>			
ApoC-III	100 ± 7	77 ± 5 ^b	83 ± 5 ^a	58 ± 6 ^e	70 ± 6 ^c	66 ± 5 ^d
ApoC-II	100 ± 4	67 ± 7 ^e	69 ± 2 ^e	37 ± 3 ^e	40 ± 3 ^e	47 ± 3 ^e
ApoE	100 ± 1	109 ± 5	99 ± 3	108 ± 4	117 ± 8 ^a	128 ± 8 ^c
ApoA-I	100 ± 6	81 ± 4	83 ± 4	78 ± 3 ^a	146 ± 7 ^e	148 ± 12 ^e
ApoB	100 ± 8	49 ± 3 ^e	69 ± 5 ^e	30 ± 3 ^e	48 ± 6 ^e	44 ± 9 ^e

Animals were dosed by oral gavage with compounds at the indicated daily dose for 1 week. Plasma determinants were measured as described in Materials and Methods. Data represent mean ± SE of the mean for the indicated number of rats per group. ANOVA, Fisher PLSD post hoc analysis was used for determination of significant mean difference compared to controls: ^a*P* < 0.05; ^b*P* < 0.01; ^c*P* < 0.005; ^d*P* < 0.0005; ^e*P* < 0.0001.